EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

EFFICACY OF FAVIPIRAVIR IN TREATING HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL

Dr. Shailendranath Biswas*, Professor Dr. S. K. Ballav, Dr. Sheikh Farid Uddin Ahmed, Dr. Mohammad Monir-Uz-Zaman, Dr. Utpal Chanda, Dr. Tahmida Khanom, Dr. Mohaiminul Haque, Dr. Ripon Roy and Dr. Avijit Kumar Mridha

ABSTRACT

Background: After the emergence of novel coronavirus disease (covid-19), several therapeutic agents of different mechanisms and groups have been tried and evaluated worldwide to reduce the toll of mortality and morbidity. But unfortunately, no such agent was proven beneficial in this regard. Methods: We conducted a double-blind, randomized, placebo-controlled trial of oral Favipiraivir in adults who got admitted into hospitals with features of respiratory tract infection and subsequently diagnosed as COVID-19 pneumonia by RT-PCR for COVID-19 test. Patients were randomly assigned to receive either Favipiravir (1600mg 12 hourly on day 1, followed by 600 mg 12 hourly daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome of the study was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. Results: We enrolled a total of 100 patients in this study randomly after considering inclusion and exclusion criteria (with 60 assigned to Favipiravir and 40 to placebo). Among the participants who received Favipiravir had an average recovery time of 08 days (95% confidence interval [CI], 07 to 09), as compared with 12.5days (95% CI, 11 to 15) among those who received placebo. The in-hospital mortality was 1.66% with Favipiravir and 05% with placebo by day 15. Though there were some mild to moderate adverse drug reactions in both groups no serious adverse event was reported in any group. Conclusion: Our study demonstrates that Favipiravir is superior to placebo in hastening clinical recovery and reducing mortality in hospitalized mild to moderate COVID-19 disease.

Keywords: SARS-CoV-2, Coronavirus, Placebo, Recovery Time, Oxygen Saturation, Mechanical Ventilation.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 September 2021 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR: SEPTEMBER ISSUE PUBLISHED

    SEPTEMBER Issue has been successfully launched on 1 September 2021.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )